News

Mylan has announced that its subsidiary Mylan Pharmaceuticals has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa tablets USP, 10mg/100mg,

Talyst has entered into a partnership with RXinnovate, a healthcare consultancy, to offer implementation services to Talyst’s clients in the acute care industry. Talyst said by partnering with

Hungary-based, Gedeon Richter in a multi-year agreement plans to adopt Phase Forward’s Clintrial product for its clinical trial data management activities. Gyorgy Nemeth, medical director at Gedeon Richter,

Aphios has been awarded a RC-1 Challenge grant (No 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health’s (NIH) American Recovery and Reinvestment

Cord Blood America is opening its new corporate headquarters and cryogenic research and storage laboratory in Las Vegas, as planned, the first week of October. The facility will

Sosei has announced the submission of the New Drug Application (NDA) for the emergency contraceptive pill SOH-075 (NorLevo) to Ministry of Health, Labour and Welfare (MHLW) by Sosei

Pfizer has announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Wyeth. The ACCC’s decision includes Pfizer’s commitment to divest certain

Sanofi-Aventis has announced the results of a head-to-head study of once-daily, 24-hour basal insulin Lantus compared to twice-daily insulin Detemir. The study was a head-to-head, randomised, non-inferiority controlled

Novartis has posted initial results from the two-year phase III FREEDOMS study, which shows that oral FTY720 (fingolimod) was superior to placebo in reducing both relapses and disability